Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized Trial

Rong Tang(Tulane University), Jingxin Li(Beijing Tongren Hospital), Peng Wan(Academy of Military Medical Sciences), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Shipo Wu(Academy of Military Medical Sciences), Jin Zhong, Jin-Bo Gou, Fengjuan Shi(Jiangsu Provincial Center for Disease Control and Prevention), Hui Zheng(Southeast University), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Tao Zhu, Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Busen Wang(Academy of Military Medical Sciences), Zhuo-Pei Li(Nanjing Medical University), Xiaolong Li(China Pharmaceutical University), Xue Wang(Ningxia Hui Autonomous Region Peoples Hospital), Yin Chen(Southern Medical University), Jingxian Liu(Jiangsu Provincial Center for Disease Control and Prevention), Xiaoyu Xu, Xiaoqin Chen(North Sichuan Medical University), Xiaoyin Zhang(Southeast University), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Lihua Hou(Academy of Military Medical Sciences), Jiahong Zhu(Taiwan Centers for Disease Control), Zhizhou Song
SSRN Electronic Journal
January 1, 2022
Cited by 3


Related Papers